Determination of Iron Absorption Mechanism From Ferrous Fumarate With GOS
Launched by ISABELLE HERTER-AEBERLI · Jun 21, 2019
Trial Information
Current as of May 25, 2025
Completed
Keywords
ClinConnect Summary
Iron is an important mineral in our body and fulfills essential functions such as for example oxygen transport from the lungs to the tissues. Iron deficiency is still the most common and widespread nutritional disorder in the world according to WHO. Common iron supplements all have their limitations in terms of availability and compatibility. Prebiotic fibers, such as galacto-oligosaccharides (GOS), selectively enhance growth of beneficial colonic bacteria. Prebiotics in general enhance the production of short-chain fatty acids (SCFAs) and thereby decrease luminal pH. Through the reduction ...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Female, 18 to 45 years old
- • SF levels 15-30 µg/L
- • Normal body Mass Index (18.5-24.9 kg/m2)
- • Body weight \<70 kg
- • Signed informed consent
- Exclusion Criteria:
- • Severe anaemia (Hb \< 80 g/L)
- • Elevated CRP \>10.0 mg/L
- • Any metabolic, gastrointestinal kidney or chronic disease such as diabetes, renal failure, hepatic dysfunction, hepatitis, hypertension, cancer or cardiovascular diseases (according to the participants own statement)
- • Continuous/long-term use of medication during the whole studies (except for contraceptives)
- • Consumption of mineral and vitamin supplements within 2 weeks prior to 1st supplement administration, including pre- and-or probiotics supplements (excluding foods and beverages with life cultures such as yoghurt, raw milk cheese and kombucha)
- • Blood transfusion, blood donation or significant blood loss (accident, surgery) over the past 4 months
- • Difficulties with blood sampling
- • Use of antibiotics over the past month
- • Known hypersensitivity to iron supplements in the given amount, GOS, or lactose
- • Women who are pregnant or breast feeding
- • Women who intend become pregnant during the course of the study
- • Lack of safe contraception, defined as: Female participants of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, inject-able, or implantable contraceptives, or intrauterine contraceptive devices, or who are not using any other method considered sufficiently reliable by the investigator in individual cases
- • Known or suspected non-compliance, drug or alcohol (more than 2 drinks/day) abuse -
- • Smokers (\> 1 cigarette per week)
- • Inability to follow the procedures of the study, e.g. due to language problems, self-- reported psychological disorders, etc. of the participant
- • Enrollment of the investigator, his/her family members, employees and other dependent persons
About Isabelle Herter Aeberli
Isabelle Herter-Aeberli is a distinguished clinical trial sponsor dedicated to advancing medical research and improving patient outcomes through innovative clinical studies. With a strong emphasis on ethics and regulatory compliance, she leads initiatives that explore novel therapeutic interventions across various therapeutic areas. Her extensive experience in clinical trial design and management, coupled with a commitment to collaboration with healthcare professionals and stakeholders, ensures the successful execution of trials that prioritize patient safety and scientific integrity. Under her guidance, the organization strives to contribute valuable insights to the medical community and enhance the quality of care for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Zurich, , Switzerland
Patients applied
Trial Officials
Isabelle Herter-Aeberli, Dr.
Principal Investigator
Laboratory of Human Nutrition ETH Zürich
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials